Cardiovascular disease in patients with chronic kidney disease. A clinical review.
Identifieur interne : 000233 ( Main/Exploration ); précédent : 000232; suivant : 000234Cardiovascular disease in patients with chronic kidney disease. A clinical review.
Auteurs : M. Kaisar ; N. Isbel ; D W JohnsonSource :
- Minerva urologica e nefrologica = The Italian journal of urology and nephrology [ 0393-2249 ] ; 2007.
Descripteurs français
- KwdFr :
- Anémie (complications), Cardiomyopathies (complications), Dialyse rénale (effets indésirables), Défaillance rénale chronique (complications), Défaillance rénale chronique (métabolisme), Défaillance rénale chronique (thérapie), Facteurs de risque (MeSH), Humains (MeSH), Hyperhomocystéinémie (complications), Hyperlipidémies (complications), Maladie chronique (MeSH), Maladies cardiovasculaires (étiologie), Maladies du rein (complications), Maladies du rein (thérapie), Maladies osseuses métaboliques (complications), Stress oxydatif (MeSH).
- MESH :
- effets indésirables : Anémie, Cardiomyopathies, Dialyse rénale, Défaillance rénale chronique, Hyperhomocystéinémie, Hyperlipidémies, Maladies du rein, Maladies osseuses métaboliques.
- métabolisme : Défaillance rénale chronique.
- thérapie : Défaillance rénale chronique, Maladies du rein.
- étiologie : Maladies cardiovasculaires.
- Facteurs de risque, Humains, Maladie chronique, Stress oxydatif.
English descriptors
- KwdEn :
- Anemia (complications), Bone Diseases, Metabolic (complications), Cardiomyopathies (complications), Cardiovascular Diseases (etiology), Chronic Disease (MeSH), Humans (MeSH), Hyperhomocysteinemia (complications), Hyperlipidemias (complications), Kidney Diseases (complications), Kidney Diseases (therapy), Kidney Failure, Chronic (complications), Kidney Failure, Chronic (metabolism), Kidney Failure, Chronic (therapy), Oxidative Stress (MeSH), Renal Dialysis (adverse effects), Risk Factors (MeSH).
- MESH :
- adverse effects : Renal Dialysis.
- complications : Anemia, Bone Diseases, Metabolic, Cardiomyopathies, Hyperhomocysteinemia, Hyperlipidemias, Kidney Diseases, Kidney Failure, Chronic.
- etiology : Cardiovascular Diseases.
- metabolism : Kidney Failure, Chronic.
- therapy : Kidney Diseases, Kidney Failure, Chronic.
- Chronic Disease, Humans, Oxidative Stress, Risk Factors.
Abstract
Cardiovascular disease (CVD) remains the most common cause of premature death in the chronic kidney disease (CKD) population. Individuals with CKD are at 10-20 times greater risk of cardiac death than controls without CKD, despite stratification for age, race, sex and diabetes. Heightened CVD mortality begins with mild kidney disease and rises further with more advanced kidney disease. Traditional risk factors account for up to 50% of cardiovascular disease in CKD, whilst renal specific markers, including anemia, disordered bone mineral metabolism and oxidative stress, also likely contribute to the total cardiovascular burden in CKD. Despite the increased mortality, there has been a dearth of interventional cardiovascular randomized controlled trials (RCTs) in the CKD population. Furthermore, many patients with kidney disease have been excluded from the majority of mainstream cardiovascular interventional trials. While recently published RCTs on traditional and non-traditional risk factors including dyslipidemia (PPP, 4D and ALERT, VA-HIT), cardiomyopathy (FOSIDIAL, telmisartan, carvedilol), anemia (US Normal Hematocrit, CHOIR and CREATE trials), hyperhomocystenemia (ASFAST, US folic acid trial, HOST), disordered bone mineral metabolism (Cunningham meta-analysis, DCOR), oxidative stress therapy (SPACE, HOPE and ATIC, N-acetylcysteine) and multidisciplinary multiple cardiovascular risk factor intervention clinics (LANDMARK) have added to the available pool of clinical data, level 1 clinical evidence remains significantly lacking. The negative findings in many of these trials highlight the potential dangers of extrapolating findings from non kidney disease patients to those with CKD. Further large, well-designed trials are urgently required to address this issue.
PubMed: 17912225
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiovascular disease in patients with chronic kidney disease. A clinical review.</title><author><name sortKey="Kaisar, M" sort="Kaisar, M" uniqKey="Kaisar M" first="M" last="Kaisar">M. Kaisar</name><affiliation><nlm:affiliation>Centre for Kidney Disease Research, University of Queensland at Princess, Alexandra Hospital, Brisbane, QLD Australia.</nlm:affiliation><wicri:noCountry code="subField">QLD Australia</wicri:noCountry></affiliation></author><author><name sortKey="Isbel, N" sort="Isbel, N" uniqKey="Isbel N" first="N" last="Isbel">N. Isbel</name></author><author><name sortKey="Johnson, D W" sort="Johnson, D W" uniqKey="Johnson D" first="D W" last="Johnson">D W Johnson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17912225</idno><idno type="pmid">17912225</idno><idno type="wicri:Area/Main/Corpus">000229</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000229</idno><idno type="wicri:Area/Main/Curation">000226</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000226</idno><idno type="wicri:Area/Main/Exploration">000226</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cardiovascular disease in patients with chronic kidney disease. A clinical review.</title><author><name sortKey="Kaisar, M" sort="Kaisar, M" uniqKey="Kaisar M" first="M" last="Kaisar">M. Kaisar</name><affiliation><nlm:affiliation>Centre for Kidney Disease Research, University of Queensland at Princess, Alexandra Hospital, Brisbane, QLD Australia.</nlm:affiliation><wicri:noCountry code="subField">QLD Australia</wicri:noCountry></affiliation></author><author><name sortKey="Isbel, N" sort="Isbel, N" uniqKey="Isbel N" first="N" last="Isbel">N. Isbel</name></author><author><name sortKey="Johnson, D W" sort="Johnson, D W" uniqKey="Johnson D" first="D W" last="Johnson">D W Johnson</name></author></analytic><series><title level="j">Minerva urologica e nefrologica = The Italian journal of urology and nephrology</title><idno type="ISSN">0393-2249</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anemia (complications)</term><term>Bone Diseases, Metabolic (complications)</term><term>Cardiomyopathies (complications)</term><term>Cardiovascular Diseases (etiology)</term><term>Chronic Disease (MeSH)</term><term>Humans (MeSH)</term><term>Hyperhomocysteinemia (complications)</term><term>Hyperlipidemias (complications)</term><term>Kidney Diseases (complications)</term><term>Kidney Diseases (therapy)</term><term>Kidney Failure, Chronic (complications)</term><term>Kidney Failure, Chronic (metabolism)</term><term>Kidney Failure, Chronic (therapy)</term><term>Oxidative Stress (MeSH)</term><term>Renal Dialysis (adverse effects)</term><term>Risk Factors (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anémie (complications)</term><term>Cardiomyopathies (complications)</term><term>Dialyse rénale (effets indésirables)</term><term>Défaillance rénale chronique (complications)</term><term>Défaillance rénale chronique (métabolisme)</term><term>Défaillance rénale chronique (thérapie)</term><term>Facteurs de risque (MeSH)</term><term>Humains (MeSH)</term><term>Hyperhomocystéinémie (complications)</term><term>Hyperlipidémies (complications)</term><term>Maladie chronique (MeSH)</term><term>Maladies cardiovasculaires (étiologie)</term><term>Maladies du rein (complications)</term><term>Maladies du rein (thérapie)</term><term>Maladies osseuses métaboliques (complications)</term><term>Stress oxydatif (MeSH)</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Renal Dialysis</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Anemia</term><term>Bone Diseases, Metabolic</term><term>Cardiomyopathies</term><term>Hyperhomocysteinemia</term><term>Hyperlipidemias</term><term>Kidney Diseases</term><term>Kidney Failure, Chronic</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anémie</term><term>Cardiomyopathies</term><term>Dialyse rénale</term><term>Défaillance rénale chronique</term><term>Hyperhomocystéinémie</term><term>Hyperlipidémies</term><term>Maladies du rein</term><term>Maladies osseuses métaboliques</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Kidney Failure, Chronic</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Défaillance rénale chronique</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Kidney Diseases</term><term>Kidney Failure, Chronic</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Défaillance rénale chronique</term><term>Maladies du rein</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Maladies cardiovasculaires</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Chronic Disease</term><term>Humans</term><term>Oxidative Stress</term><term>Risk Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs de risque</term><term>Humains</term><term>Maladie chronique</term><term>Stress oxydatif</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cardiovascular disease (CVD) remains the most common cause of premature death in the chronic kidney disease (CKD) population. Individuals with CKD are at 10-20 times greater risk of cardiac death than controls without CKD, despite stratification for age, race, sex and diabetes. Heightened CVD mortality begins with mild kidney disease and rises further with more advanced kidney disease. Traditional risk factors account for up to 50% of cardiovascular disease in CKD, whilst renal specific markers, including anemia, disordered bone mineral metabolism and oxidative stress, also likely contribute to the total cardiovascular burden in CKD. Despite the increased mortality, there has been a dearth of interventional cardiovascular randomized controlled trials (RCTs) in the CKD population. Furthermore, many patients with kidney disease have been excluded from the majority of mainstream cardiovascular interventional trials. While recently published RCTs on traditional and non-traditional risk factors including dyslipidemia (PPP, 4D and ALERT, VA-HIT), cardiomyopathy (FOSIDIAL, telmisartan, carvedilol), anemia (US Normal Hematocrit, CHOIR and CREATE trials), hyperhomocystenemia (ASFAST, US folic acid trial, HOST), disordered bone mineral metabolism (Cunningham meta-analysis, DCOR), oxidative stress therapy (SPACE, HOPE and ATIC, N-acetylcysteine) and multidisciplinary multiple cardiovascular risk factor intervention clinics (LANDMARK) have added to the available pool of clinical data, level 1 clinical evidence remains significantly lacking. The negative findings in many of these trials highlight the potential dangers of extrapolating findings from non kidney disease patients to those with CKD. Further large, well-designed trials are urgently required to address this issue.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17912225</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0393-2249</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Minerva urologica e nefrologica = The Italian journal of urology and nephrology</Title></Journal><ArticleTitle>Cardiovascular disease in patients with chronic kidney disease. A clinical review.</ArticleTitle><Pagination><MedlinePgn>281-97</MedlinePgn></Pagination><Abstract><AbstractText>Cardiovascular disease (CVD) remains the most common cause of premature death in the chronic kidney disease (CKD) population. Individuals with CKD are at 10-20 times greater risk of cardiac death than controls without CKD, despite stratification for age, race, sex and diabetes. Heightened CVD mortality begins with mild kidney disease and rises further with more advanced kidney disease. Traditional risk factors account for up to 50% of cardiovascular disease in CKD, whilst renal specific markers, including anemia, disordered bone mineral metabolism and oxidative stress, also likely contribute to the total cardiovascular burden in CKD. Despite the increased mortality, there has been a dearth of interventional cardiovascular randomized controlled trials (RCTs) in the CKD population. Furthermore, many patients with kidney disease have been excluded from the majority of mainstream cardiovascular interventional trials. While recently published RCTs on traditional and non-traditional risk factors including dyslipidemia (PPP, 4D and ALERT, VA-HIT), cardiomyopathy (FOSIDIAL, telmisartan, carvedilol), anemia (US Normal Hematocrit, CHOIR and CREATE trials), hyperhomocystenemia (ASFAST, US folic acid trial, HOST), disordered bone mineral metabolism (Cunningham meta-analysis, DCOR), oxidative stress therapy (SPACE, HOPE and ATIC, N-acetylcysteine) and multidisciplinary multiple cardiovascular risk factor intervention clinics (LANDMARK) have added to the available pool of clinical data, level 1 clinical evidence remains significantly lacking. The negative findings in many of these trials highlight the potential dangers of extrapolating findings from non kidney disease patients to those with CKD. Further large, well-designed trials are urgently required to address this issue.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaisar</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Kidney Disease Research, University of Queensland at Princess, Alexandra Hospital, Brisbane, QLD Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isbel</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>D W</ForeName><Initials>DW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Minerva Urol Nefrol</MedlineTA><NlmUniqueID>8503649</NlmUniqueID><ISSNLinking>0393-2249</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000740" MajorTopicYN="N">Anemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001851" MajorTopicYN="N">Bone Diseases, Metabolic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="N">Cardiomyopathies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020138" MajorTopicYN="N">Hyperhomocysteinemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006949" MajorTopicYN="N">Hyperlipidemias</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="N">Renal Dialysis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>93</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17912225</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Isbel, N" sort="Isbel, N" uniqKey="Isbel N" first="N" last="Isbel">N. Isbel</name><name sortKey="Johnson, D W" sort="Johnson, D W" uniqKey="Johnson D" first="D W" last="Johnson">D W Johnson</name><name sortKey="Kaisar, M" sort="Kaisar, M" uniqKey="Kaisar M" first="M" last="Kaisar">M. Kaisar</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SanteChoraleV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000233 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000233 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SanteChoraleV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:17912225
|texte= Cardiovascular disease in patients with chronic kidney disease. A clinical review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:17912225" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SanteChoraleV4
| This area was generated with Dilib version V0.6.37. |  |